The Influence of Screening for Precancerous Lesions on Family-Based Genetic Association Tests: An Example of Colorectal Polyps and Cancer

被引:5
|
作者
Schmit, Stephanie L. [1 ,2 ]
Figueiredo, Jane C. [1 ,2 ]
Cortessis, Victoria K. [1 ,2 ,3 ]
Thomas, Duncan C. [1 ,2 ]
机构
[1] Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[2] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[3] Univ So Calif, Keck Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA
关键词
candidate gene; colorectal cancer; genetic association; polymorphisms; polyps; precursor; screening; secondary prevention; RARE-DISEASE ASSUMPTION; METHYLENETETRAHYDROFOLATE REDUCTASE; ADENOMATOUS POLYPS; CIGARETTE-SMOKING; RELATIVE RISK; COLON-CANCER; EPIDEMIOLOGY; ESTIMATORS; METABOLISM; REGISTRY;
D O I
10.1093/aje/kwv128
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Unintended consequences of secondary prevention include potential introduction of bias into epidemiologic studies estimating genotype-disease associations. To better understand such bias, we simulated a family-based study of colorectal cancer (CRC), which can be prevented by resecting screen-detected polyps. We simulated genes related to CRC development through risk of polyps (G(1)), risk of CRC but not polyps (G(2)), and progression from polyp to CRC (G(3)). Then, we examined 4 analytical strategies for studying diseases subject to secondary prevention, comparing the following: 1) CRC cases with all controls, without adjusting for polyp history; 2) CRC cases with controls, adjusting for polyp history; 3) CRC cases with only polyp-free controls; and 4) cases with either CRC or polyps with controls having neither. Strategy 1 yielded estimates of association between CRC and each G that were not substantially biased. Strategies 2-4 yielded biased estimates varying in direction according to analysis strategy and gene type. Type I errors were correct, but strategy 1 provided greater power for estimating associations with G(2) and G(3). We also applied each strategy to case-control data from the Colon Cancer Family Registry (1997-2007). Generally, the best analytical option balancing bias and power is to compare all CRC cases with all controls, ignoring polyps.
引用
收藏
页码:714 / 722
页数:9
相关论文
共 50 条
  • [1] RE: "THE INFLUENCE OF SCREENING FOR PRECANCEROUS LESIONS ON FAMILY-BASED GENETIC ASSOCIATION TESTS: AN EXAMPLE OF COLORECTAL POLYPS AND CANCER" (vol 182, pg 714, 2015)
    Schmit, S. L.
    Figueiredo, J. C.
    Cortessis, V. K.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2016, 183 (03) : 248 - 248
  • [2] Family-based screening for colorectal cancer: The Australian perspective
    Leggett, Barbara A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : S29 - S32
  • [3] Family-based association tests
    Baur, MP
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1998, 81 (06): : 460 - 460
  • [4] Family-based tests of association and/or linkage
    Whittaker, JC
    Morris, AP
    ANNALS OF HUMAN GENETICS, 2001, 65 : 407 - 419
  • [5] Power of family-based association tests
    Nsengimana, J
    Bishop, T
    Barrett, JH
    ANNALS OF HUMAN GENETICS, 2005, 69 : 771 - 771
  • [6] Family-based association tests for genomewide association scans
    Chen, Wei-Min
    Abecasis, Goncalo R.
    AMERICAN JOURNAL OF HUMAN GENETICS, 2007, 81 (05) : 913 - 926
  • [7] EFBAT: exact family-based association tests
    Kady Schneiter
    James H Degnan
    Christopher Corcoran
    Xin Xu
    Nan Laird
    BMC Genetics, 8
  • [8] Family-based tests of association in the presence of linkage
    Lake, SL
    Blacker, D
    Laird, NM
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (06) : 1515 - 1525
  • [9] EFBAT: exact family-based association tests
    Schneiter, Kady
    Degnan, James H.
    Corcoran, Christopher
    Xu, Xin
    Laird, Nan
    BMC GENETICS, 2007, 8
  • [10] Genomic screening in family-based association testing
    Amy Murphy
    Matthew B McQueen
    Jessica Su
    Peter Kraft
    Ross Lazarus
    Nan M Laird
    Christoph Lange
    Kristel Van Steen
    BMC Genetics, 6